Moshkevich Solomon sold $906K of NTRA
Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 3,410 shares of Natera, Inc. (NTRA) at an average of $265.58 ($259.98–$268.70, $0.91M total) across 7 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale amount, share count, and the fact it was executed under a pre-arranged 10b5-1 plan.
Market read
This provides a fresh insider-selling datapoint, but it is not tied to earnings, guidance, or regulatory/product events in the text.
What to watch
Traders may focus on whether multiple insiders are selling concurrently or whether the sale coincides with other company-specific catalysts, which are not present in this text.
Background
The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.
Ticker impact
Natera Form 4 shows President, Clinical Diagnostics Moshkevich Solomon sold $905,626 of NTRA shares via a 10b5-1 plan on Aug 3.
Likely limited, with any impact more sentiment-driven than fundamental.
The filing is a primary-source Form 4 and the transaction size is moderate, but the presence of a pre-arranged 10b5-1 plan reduces interpretive signal.
Market effects
Minimal; insider sales under 10b5-1 typically do not reset sector expectations for diagnostics/biotech.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; price impact could be negligible.
Key entities
- issuerNatera, Inc.
Company whose insider transaction is disclosed on Form 4.
- insiderMoshkevich Solomon
President, Clinical Diagnostics; sold 3,410 shares of NTRA on Aug 3 under a 10b5-1 plan.
